US health policy & drug pricing
Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.
Overview
Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.
US health policy & drug pricing has been the subject of significant news coverage, research, and policy discussion. Key developments include regulatory actions, clinical findings, and public health implications that affect patients, healthcare providers, and policymakers.
Trump administration proposes new rules that would increase political control over CDC science and federal research grants
CMS and FDA Launch RAPID Coverage Pathway to Accelerate Medicare Access for Breakthrough Medical Devices
Overview
U.S. prescription drug spending is projected to exceed $1 trillion in 2026, driven largely by weight-loss medications and specialty drugs. The pharmaceutical industry faces mounting pressure from federal pricing programs, with PhRMA filing a lawsuit to block the Trump administration's GLOBE pilot program that would benchmark Medicare drug prices against international rates.
Multiple policy initiatives are reshaping drug access and affordability, including the CMS-FDA RAPID Coverage Pathway for breakthrough devices, evolving Medicare coverage for Alzheimer's drugs, and ongoing debates over insurance premium increases and drug pricing transparency. The intersection of regulatory action, industry litigation, and spending trends highlights the complex landscape of American pharmaceutical policy.